A Phase 1, Randomized, Double Blind, Sponsor-open, Placebo-controlled, Dose Escalation Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Single-dose, Subcutaneous Administration Of Pf 06946860 To Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs PF-06946860 (Primary)
- Indications Cachexia
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 06 Nov 2019 Status changed from recruiting to completed.
- 20 Aug 2019 Planned End Date changed from 1 Aug 2019 to 25 Oct 2019.
- 20 Aug 2019 Planned primary completion date changed from 1 Aug 2019 to 25 Oct 2019.